Neuropsychiatric long COVID is associated with altered SARS-CoV-2-specific cellular-humoral coordination and diminished EBV-specific humoral immunity up to 12 months post-COVID-19 symptom onset

Long COVID is a chronic multisystemic condition estimated to affect approximately 400 million people worldwide. Although underlying mechanisms remain elusive, persistent SARS-CoV-2 reservoirs and Epstein-Barr virus (EBV) reactivation have been implicated. We compared SARS-CoV-2- and EBV-specific cellular and humoral immunity between 27 long COVID individuals with ≥2 neuropsychiatric symptoms and 27 matched recovered participants at 3-6 months post-COVID-19 symptom onset (PSO). Peripheral blood mononuclear cells were assessed for IFN-γ, IL-2, TNF, and granzyme B T-cell responses against SARS-CoV-2, EBV, and HCMV. Sera were evaluated for neutralizing activity against live ancestral SARS-CoV-2 and EBV, while EBV reactivation was assessed by anti-early antigen-diffuse IgG and anti-viral capsid antigen (VCA) IgM. We observed no significant differences in SARS-CoV-2-, EBV-, or HCMV-specific Th1-type/cytotoxic T-cell responses or live virus neutralization between long COVID and recovered groups at 3-6 months PSO. Although SARS-CoV-2-specific IFN-γ and IL-2 T-cell responses correlated with serological neutralizing capacity in recovered participants, no such associations were observed in the long COVID group, suggesting altered coordination between cellular and humoral immunity. EBV reactivation was only detected in one neuropsychiatric long COVID participant. However, EBV anti-VCA IgG antibody levels were significantly diminished in long COVID participants at 3-6 months PSO. Reports of fatigue at 12 months PSO were also associated with reduced EBV neutralizing capacity at 3-6 months PSO. Diminished EBV-specific humoral immunity and dysregulated coordination between SARS-CoV-2-specific cellular and humoral immunity may thus represent potential prognostic markers for neuropsychiatric long COVID development and fatigue up to 12 months PSO.IMPORTANCEWe performed a comprehensive analysis of cellular and humoral immune responses to SARS-CoV-2, Epstein-Barr virus (EBV), and human cytomegalovirus in individuals with neuropsychiatric long COVID, a subgroup that remains poorly characterized. Although no differences in virus-specific Th1-type or cytotoxic T-cell immunity were observed between individuals with long COVID and recovered individuals, altered coordination between SARS-CoV-2-specific T-cell and neutralizing humoral immunity was observed in the long COVID group at 3-6 months post-COVID-19 symptom onset (PSO). Diminished EBV-specific humoral immunity was also associated with neuropsychiatric long COVID and fatigue up to 12 months PSO. Together, these findings suggest that altered SARS-CoV-2-specific cellular-humoral immune coordination and diminished EBV-specific humoral immunity may contribute to the development or persistence of neuropsychiatric long COVID and highlight a promising future direction for mechanistic studies.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05125510.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2026-11-13
DOI
https://doi.org/10.1128/jvi.00935-26
Primary Topic
Long-Term Effects of COVID-19
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neuropsychiatric long COVID is associated with altered SARS-CoV-2-specific cellular-humoral coordination and diminished EBV-specific humoral immunity up to 12 months post-COVID-19 symptom onset

Philip Samaan, Angela M. Cheung, V. Russell, Mario Ostrowski et al.
Journal of Virology
Long-Term Effects of COVID-19
article

Neuropsychiatric long COVID is associated with altered SARS-CoV-2-specific cellular-humoral coordination and diminished EBV-specific humoral immunity up to 12 months post-COVID-19 symptom onset

Philip Samaan, Angela M. Cheung, V. Russell, Mario Ostrowski, Jeevitha Srighanthan, Patrick Budylowski, Vitaliy Matveev
article en

Abstract

Long COVID is a chronic multisystemic condition estimated to affect approximately 400 million people worldwide. Although underlying mechanisms remain elusive, persistent SARS-CoV-2 reservoirs and Epstein-Barr virus (EBV) reactivation have been implicated. We compared SARS-CoV-2- and EBV-specific cellular and humoral immunity between 27 long COVID individuals with ≥2 neuropsychiatric symptoms and 27 matched recovered participants at 3-6 months post-COVID-19 symptom onset (PSO). Peripheral blood mononuclear cells were assessed for IFN-γ, IL-2, TNF, and granzyme B T-cell responses against SARS-CoV-2, EBV, and HCMV. Sera were evaluated for neutralizing activity against live ancestral SARS-CoV-2 and EBV, while EBV reactivation was assessed by anti-early antigen-diffuse IgG and anti-viral capsid antigen (VCA) IgM. We observed no significant differences in SARS-CoV-2-, EBV-, or HCMV-specific Th1-type/cytotoxic T-cell responses or live virus neutralization between long COVID and recovered groups at 3-6 months PSO. Although SARS-CoV-2-specific IFN-γ and IL-2 T-cell responses correlated with serological neutralizing capacity in recovered participants, no such associations were observed in the long COVID group, suggesting altered coordination between cellular and humoral immunity. EBV reactivation was only detected in one neuropsychiatric long COVID participant. However, EBV anti-VCA IgG antibody levels were significantly diminished in long COVID participants at 3-6 months PSO. Reports of fatigue at 12 months PSO were also associated with reduced EBV neutralizing capacity at 3-6 months PSO. Diminished EBV-specific humoral immunity and dysregulated coordination between SARS-CoV-2-specific cellular and humoral immunity may thus represent potential prognostic markers for neuropsychiatric long COVID development and fatigue up to 12 months PSO.IMPORTANCEWe performed a comprehensive analysis of cellular and humoral immune responses to SARS-CoV-2, Epstein-Barr virus (EBV), and human cytomegalovirus in individuals with neuropsychiatric long COVID, a subgroup that remains poorly characterized. Although no differences in virus-specific Th1-type or cytotoxic T-cell immunity were observed between individuals with long COVID and recovered individuals, altered coordination between SARS-CoV-2-specific T-cell and neutralizing humoral immunity was observed in the long COVID group at 3-6 months post-COVID-19 symptom onset (PSO). Diminished EBV-specific humoral immunity was also associated with neuropsychiatric long COVID and fatigue up to 12 months PSO. Together, these findings suggest that altered SARS-CoV-2-specific cellular-humoral immune coordination and diminished EBV-specific humoral immunity may contribute to the development or persistence of neuropsychiatric long COVID and highlight a promising future direction for mechanistic studies.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05125510.

Journal of Virology
St. Michael's Hospital (CA), University Health Network (CA), University of Toronto (CA), Toronto General Hospital Research Institute (CA), Unity Health Toronto (CA), Keenan Research Centre for Biomedical Science (CA)
Ontario HIV Treatment Network, University of Toronto, Canadian Institutes of Health Research
Good health and well-being
Long-Term Effects of COVID-19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon